Shandong Xinhua Pharmaceutical (000756.SZ): Nimodipine Tablets Pass Generic Drug Consistency Evaluation

Shandong Xinhua Pharmaceutical (000756.SZ) announced that recently, the company received the "Drug Supplementary Application Approval Notice" for Nimodipine Tablets issued upon approval by the National Medical Products Administration, and the product has passed the generic drug quality and efficacy consistency evaluation. It is reported that this drug, used as continued treatment after prior use of Nimodipine Injection, can prevent and treat ischemic neurological damage caused by cerebral vasospasm following aneurysmal subarachnoid hemorrhage. The drug can also be used to treat senile cerebral dysfunction, such as memory loss, disorientation and attention impairment, and mood swings. Before treatment, it should be determined that these symptoms are not caused by underlying diseases requiring special treatment.